These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35398727)

  • 1. The correlation between genetic factors and freezing of gait in patients with Parkinson's disease.
    Radojević B; Dragašević-Mišković NT; Marjanović A; Branković M; Milovanović A; Petrović I; Svetel M; Jančić I; Stanisavljević D; Milićević O; Savić MM; Kostić VS
    Parkinsonism Relat Disord; 2022 May; 98():7-12. PubMed ID: 35398727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Genetic Analysis of Psychosis in Parkinson's Disease.
    Radojević B; Dragašević-Mišković NT; Marjanović A; Branković M; Dobričić V; Milovanović A; Tomić A; Svetel M; Petrović I; Jančić I; Stanisavljević D; Savić MM; Kostić VS
    J Parkinsons Dis; 2021; 11(4):1973-1980. PubMed ID: 34151861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epistatic effect of Ankyrin repeat and kinase domain containing 1 - Dopamine receptor D2 and catechol-o-methyltransferase single nucleotide polymorphisms on the risk for hazardous use of alcohol in Lithuanian population.
    Kaminskaite M; Jokubka R; Janaviciute J; Lelyte I; Sinkariova L; Pranckeviciene A; Borutaite V; Bunevicius A
    Gene; 2021 Jan; 765():145107. PubMed ID: 32889058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson's disease.
    Miller NS; Chou KL; Bohnen NI; Müller MLTM; Seidler RD
    Parkinsonism Relat Disord; 2018 Mar; 48():54-60. PubMed ID: 29249680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
    Rieck M; Schumacher-Schuh AF; Altmann V; Francisconi CL; Fagundes PT; Monte TL; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2012 Nov; 13(15):1701-10. PubMed ID: 23171335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study.
    Amboni M; Stocchi F; Abbruzzese G; Morgante L; Onofrj M; Ruggieri S; Tinazzi M; Zappia M; Attar M; Colombo D; Simoni L; Ori A; Barone P; Antonini A;
    Parkinsonism Relat Disord; 2015 Jun; 21(6):644-9. PubMed ID: 25899545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Catechol-O-Methyltransferase Gene rs4680 Polymorphism and Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta-Analysis and Systematic Review.
    Dwivedi A; Dwivedi N; Kumar A; Singh VK; Pathak A; Chaurasia RN; Mishra VN; Mohanty S; Joshi D
    J Geriatr Psychiatry Neurol; 2023 Mar; 36(2):98-106. PubMed ID: 35603896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson's disease: a prospective controlled study.
    Vercruysse S; Vandenberghe W; Münks L; Nuttin B; Devos H; Nieuwboer A
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):871-7. PubMed ID: 24396010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.
    Dos Santos EUD; da Silva IIFG; Asano AGC; Asano NMJ; De Mascena Diniz Maia M; de Souza PRE
    Mol Biol Rep; 2020 Nov; 47(11):8997-9004. PubMed ID: 33151475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa responsive freezing of gait is associated with reduced norepinephrine transporter binding in Parkinson's disease.
    McKay JL; Nye J; Goldstein FC; Sommerfeld B; Smith Y; Weinshenker D; Factor SA
    Neurobiol Dis; 2023 Apr; 179():106048. PubMed ID: 36813207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-year population-based study of freezing of gait in Parkinson's disease.
    Forsaa EB; Larsen JP; Wentzel-Larsen T; Alves G
    Parkinsonism Relat Disord; 2015 Mar; 21(3):254-8. PubMed ID: 25603767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia.
    Bartels AL; Balash Y; Gurevich T; Schaafsma JD; Hausdorff JM; Giladi N
    J Clin Neurosci; 2003 Sep; 10(5):584-8. PubMed ID: 12948464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population.
    Kiyohara C; Miyake Y; Koyanagi M; Fujimoto T; Shirasawa S; Tanaka K; Fukushima W; Sasaki S; Tsuboi Y; Yamada T; Oeda T; Shimada H; Kawamura N; Sakae N; Fukuyama H; Hirota Y; Nagai M;
    BMC Neurol; 2011 Jul; 11():89. PubMed ID: 21781348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
    Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
    Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease.
    Dos Santos EUD; Sampaio TF; Tenório Dos Santos AD; Bezerra Leite FC; da Silva RC; Crovella S; Asano AGC; Asano NMJ; de Souza PRE
    J Pharm Pharmacol; 2019 Feb; 71(2):206-212. PubMed ID: 30353564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa alters resting-state functional connectivity more selectively in Parkinson's disease with freezing of gait.
    Potvin-Desrochers A; Atri A; Moreno AM; Paquette C
    Eur J Neurosci; 2023 Jan; 57(1):163-177. PubMed ID: 36251568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.